Abstract
BACKGROUND
It has been hypothesized that early exposure to thimerosal, a mercury-containing preservative used in vaccines and immune
globulin preparations, is associated with neuropsychological deficits in children.
METHODS
We enrolled 1047 children between the ages of 7 and 10 years and administered standardized tests assessing 42 neuropsychological
outcomes. (We did not assess autism-spectrum disorders.) Exposure to mercury from thimerosal was determined from computerized
immunization records, medical records, personal immunization records, and parent interviews. Information on potential confounding
factors was obtained from the interviews and medical charts. We assessed the association between current neuropsychological
performance and exposure to mercury during the prenatal period, the neonatal period (birth to 28 days), and the first 7 months
of life.
RESULTS
Among the 42 neuropsychological outcomes, we detected only a few significant associations with exposure to mercury from thimerosal.
The detected associations were small and almost equally divided between positive and negative effects. Higher prenatal mercury
exposure was associated with better performance on one measure of language and poorer performance on one measure of attention
and executive functioning. Increasing levels of mercury exposure from birth to 7 months were associated with better performance
on one measure of fine motor coordination and on one measure of attention and executive functioning. Increasing mercury exposure
from birth to 28 days was associated with poorer performance on one measure of speech articulation and better performance
on one measure of fine motor coordination.
CONCLUSIONS
Our study does not support a causal association between early exposure to mercury from thimerosal-containing vaccines and
immune globulins and deficits in neuropsychological functioning at the age of 7 to 10 years.
Links
Authors
Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F, Vaccine Safety Datalink Team
Institution
National Center for Immunizations and Respiratory Diseases, Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. wct2@cdc.gov
Source
The New England journal of medicine 357:13 2007 Sep 27 pg 1281-92MeSH
ChildChild Development
Developmental Disabilities
Environmental Exposure
Ethylmercury Compounds
Female
Humans
Immunoglobulins
Infant
Infant, Newborn
Intelligence
Male
Neuropsychological Tests
Pregnancy
Prenatal Exposure Delayed Effects
Preservatives, Pharmaceutical
Regression Analysis
Thimerosal
Vaccines
Pub Type(s)
Journal ArticleResearch Support, U.S. Gov't, P.H.S.
Language
eng
PubMed ID
17898097
Log In

